Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 282

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millennium

Open access
Negro-Vilar, A.·1999·Journal of Clinical Endocrinology & Metabolism

Abstract

Androgen therapy, using injectable, oral and more recently, transdermal preparations, has been available to physicians for many years to treat a variety of male disorders; to a lesser degree, their use has been extended to some female indications. Unlike female sex hormone therapies, which have found extensive use and applications in the fields of hormone replacement, reproductive disorders, gynecological cancers, and contraception, androgen therapy has not been widespread. A more widely accepted use of androgen therapy has been hampered by the lack of orally active preparations with good efficacy and, particularly, a safe profile. Progress has been limited over the last three decades in developing synthetic molecules that could separate androgenic activities considered desirable (i.e., anabolic) from others that were undesirable or had dose-limiting side effects (1). The abuse of synthetic anabolic steroids by athletes and body builders has contributed to the general perception of certain negative side effects (i.e., aggressive behavior), effects that we do not expect to see with replacement regimens of testosterone or other androgen receptor agonists that target judicious restoration of physiological functions normally regulated by endogenous androgens. Recent advances clearly indicate that androgen therapy is about to experience a fundamental change, both in the extent of use and in the range of applications that may benefit from these upcoming advances. Several factors have and will continue to contribute to this change. First, the significant advances of hormone replacement therapy (HRT) in postmenopausal females and the expansion and application of HRT to treat and prevent major disorders such as osteoporosis, cardiovascular disease, breast cancer, mood and cognition, among others, have clearly established the value of novel HRT therapies for improving women’s health (2–4), and by extrapolation, they clearly point out the potential for similar approaches to address men’s health disorders. Second, the development and marketing of novel selective estrogen receptor modulators (SERMs) has provided both preclinical and clinical proof-of-concept that we can develop molecules with a great degree of tissue selectivity targeting the estrogen receptor to eliminate undesired side effects and to maintain (and in the future to enhance) the positive, protective effects of selective transcriptional receptor activation (3–7). Third, significant advances in our understanding of nuclear receptor activation and function have provided the molecular underpinnings for new drug development efforts to design and bring forward a new generation of tissue-selective molecules targeting steroid and other nuclear receptors. Proof-of-concept for tissue selectivity has now been extended to many compounds interacting with different nuclear receptors, such as the estrogen (ER), progesterone (PR), androgen (AR), retinoid (RAR/RXR), and peroxisome proliferation activated receptors (PPARs), among others (6–11). With the information described above, we have been able to chart a development path and create a profile of desired activity and selective indications for a new class of molecules targeting the androgen receptor. We have chosen the term selective androgen receptor modulators (SARMs) after the terminology currently used for similar molecules targeting the estrogen receptor. Below we briefly describe the molecular mechanisms underlying the potential for selective modulation of AR by different ligands and the opportunities that novel SARMs bring to therapies for broad, as well as selective, uses of androgen therapy, in men as well as in women. The AR is a transcription factor and a member of the extended family of nuclear receptors. As such, it shares significant homology in terms of structure with the other members of the family, including specific protein subdomains that either activate or repress gene activity. Current evidence indicates that these activation domains represent surfaces in the receptor that are induced or exposed upon hormone or ligand-binding in such a manner that they facilitate the interaction of the specific domain or surface with selected proteins named coactivators or corepressors (5, 12). These proteins are part of an expanding family of molecules, and several have been found to bind directly to AR, namely CBP/p300 (13), GRIP1 (14), ARA 54,55 and 70 (15, 16), and Tip60 (17). Each selective ligand, upon binding to the receptor, may drive it into a distinct conformation that exposes activation or interaction surfaces resulting in recruitment of specific cofactors as revealed by structural studies (12). In addition, tissue expression or relative concentration of different cofactors may vary. Recently, a testis-specific cofactor, ARIP-3, has been described (18) that modulates AR-dependent transcriptional activity. Motif-driven interactions have been described that can modify the affinity of a given cofactor for

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.84.10.3459

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 282

Metadata

Authors
Negro-Vilar, A.
Venue
Journal of Clinical Endocrinology & Metabolism
Published
1999-10-01
Volume
84
Issue
10
Pages
3459-3462
ISSN
0021-972X (ISSN-L)
OpenAlex
W2015518137
Cited by
282
References
27
FWCI
8.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millennium. https://app.cochat.ai/papers/10.1210/jc.84.10.3459
The paper
Negro-Vilar, A. (1999). Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millennium. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.84.10.3459

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.